Skip to main content
SpringerLink
Log in

Metformin SR cost saving versus metformin IR

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 euros

Reference

  • Gout-Zwart JJ, et al. Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands. PharmacoEconomics-Open : 18 Sep 2019. Available from: URL: https://doi.org/10.1007/s41669-019-00179-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Metformin SR cost saving versus metformin IR. PharmacoEcon Outcomes News 838, 17 (2019). https://doi.org/10.1007/s40274-019-6262-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6262-2

Search

Navigation